Application of Bioinformatics for the search of novel anti-viral therapies: Rational design of anti-herpes agents

Current Bioinformatics

Volumn 6, Issue 1, 2011, Pages 81-93

  Speck Planche, Alejandro ^a   Cordeiro, M Natália D S ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anti herpetic activity; DNA polymerase and protease inhibitors; Fragment; Linear discriminant analysis; Molecular docking; QSAR

Indexed keywords

BIOINFORMATICS; COMPUTATIONAL CHEMISTRY; DISCRIMINANT ANALYSIS; DISEASE CONTROL; DRUG INTERACTIONS; NEURODEGENERATIVE DISEASES;

ANTI-HERPETIC ACTIVITY; ANTIVIRAL THERAPY; DNA-POLYMERASE INHIBITOR; FRAGMENT; LINEAR DISCRIMINANT ANALYZE; MOLECULAR DOCKING; PROTEASE INHIBITOR; QSAR; RATIONAL DESIGN; VIRAL DISEASE;

VIRUSES;

ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; DEOXYGUANOSINE; DNA POLYMERASE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; PENCICLOVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BIOINFORMATICS; DRUG DESIGN; MATHEMATICAL MODEL; MOLECULAR DOCKING; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; VIRUS CLASSIFICATION;

HERPES; HERPESVIRIDAE; SIMPLEXVIRUS;

EID: 79953904679     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489311795222392     Document Type: Article

References (153)

1. th ed. Arizona: McGraw Hill 2004.
2. th ed. Galveston, Texas, University of Texas Medical Branch 1996.
3. Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. national institute of allergy and infectious diseases collaborative antiviral study. N Engl J Med 1977; 297: 289-94.
4. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer, HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977; 74: 5716-20.
5. Furman PA, St Clair MH, Fyfe JA, Rideout JL, Keller PM, Elion GB. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl) guanine and its triphosphate. J Virol 1979; 32: 72-7.
6. Mayers DL. Antimicrobial drug resistance: mechanisms of drug resistance. Dordrecht, Heidelberg, London, New York Humana Press 2009.
7. Caballero J, Fernandez M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr Top Med Chem 2008; 8: 1580-605.
8. Duardo-Sanchez A, Patlewicz G, Lopez-Diaz A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr Top Med Chem 2008; 8: 1666-75.
9. Gonzalez MP, Teran C, Saiz-Urra L, Teijeira M. Variable selection methods in QSAR: an overview. Curr Top Med Chem 2008; 8: 1606-27.
10. Gonzalez-Diaz H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr Top Med Chem 2008; 8: 1554.
11. Gonzalez-Diaz H, Prado-Prado F, Ubeira FM. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem 2008; 8: 1676-90.
12. Helguera, AM, Combes RD, Gonzalez MP, Cordeiro MNDS. Applications of 2D descriptors in drug design: a DRAGON tale. Curr Top Med Chem 2008; 8: 1628-55.
13. Ivanciuc O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr Top Med Chem 2008; 8: 1691-709.
14. Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008; 8: 1555-72.
15. Wang JF, Wei DQ, Chou KC. Drug candidates from traditional chinese medicines. Curr Top Med Chem 2008; 8: 1656-65.
16. Wang JF, Wei DQ, Chou KC. Pharmacogenomics and personalized use of drugs. Curr Top Med Chem 2008; 8: 1573-9.
17. Torrens F, Castellano G. Topological charge-transfer indices: from small molecules to proteins. Curr Proteomics 2009: 204-13.
18. Concu R, Dea-Ayuela MA, Perez-Montoto LG, et al. 3D entropy and moments prediction of enzyme classes and experimentaltheoretic study of peptide fingerprints in Leishmania parasites. Biochim Biophys Acta 2009; 1794: 1784-94.
19. Ivanciuc O. Machine learning Quantitative Structure-Activity Relationships (QSAR) for peptides binding to Human Amphiphysin-1 SH3 domain. Curr Proteomics 2009; 4: 289-302.
20. Vilar S, Gonzalez-Diaz H, Santana L, Uriarte E. A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J Theor Biol 2009; 261: 449-58.
21. Giuliani A, Di Paola L, Setola R. Proteins as Networks: a mesoscopic approach using haemoglobin molecule as case study. Curr Proteomics 2009; 6: 235-45.
22. Chou KC. Pseudo amino acid composition and its applications in bioinformatics, proteomics and system biology. Curr Proteomics 2009; 6: 262-74.
23. Chen J, Shen B. Computational analysis of amino acid mutation: a proteome wide perspective. Curr Proteomics 2009; 6: 228-34.
24. Zhong WZ, Zhan J, Kang P, Yamazaki S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr Drug Metab 2010; 11: 296-306.
25. Wang JF, Chou KC. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab 2010; 11: 342-6.
26. Mrabet Y, Semmar N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr Drug Metab 2010; 11: 315-41.
27. Martinez-Romero M, Vazquez-Naya JM, Rabunal JR, et al. Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. Curr Drug Metab 2010; 11: 347-68.
28. Khan MT. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr Drug Metab 2010; 11: 285-95.
29. Gonzalez-Diaz H, Duardo-Sanchez A, Ubeira FM, et al. Review of march-inside & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr Drug Metab 2010; 11: 379-406.
30. Gonzalez-Diaz H. Network topological indices, drug metabolism, and distribution. Curr Drug Metab 2010; 11: 283-4.
31. Garcia I, Diop YF, Gomez G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr Drug Metab 2010; 11: 307-14.
32. Chou KC. Graphic rule for drug metabolism systems. Curr Drug Metab 2010; 11: 369-78.
33. Concu R, Podda G, Ubeira FM, Gonzalez-Diaz H. Review of QSAR models for enzyme classes of drug targets: Theoretical background and applications in parasites, hosts, and other organisms. Curr Pharm Design 2010; 16: 2710-23.
34. Estrada E, Molina E, Nodarse D, Uriarte E. Structural contributions of substrates to their binding to P-Glycoprotein. A tops-mode approach. Curr Pharm Design 2010; 16: 2676-709.
35. Garcia I, Fall Y, Gomez G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr Pharm Design 2010; 16: 2666-75.
36. Gonzalez-Diaz H. QSAR and complex networks in pharmaceutical design, microbiology, parasitology, toxicology, cancer, and neurosciences. Curr Pharm Design 2010; 16: 2598-600.
37. Gonzalez-Diaz H, Romaris F, Duardo-Sanchez A, et al. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues. Curr Pharm Design 2010; 16: 2737-64.
38. Marrero-Ponce Y, Casanola-Martin GM, Khan MT, Torrens F, Rescigno A, Abad C. Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr Pharm Design 2010; 16: 2601-24.
39. Munteanu CR, Fernandez-Blanco E, Seoane JA, et al. Drug discovery and design for complex diseases through QSAR computational methods. Curr Pharm Design 2010; 16: 2640-55.
40. Roy K, Ghosh G. Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity. Curr Pharm Design 2010; 16: 2625-39.
41. Speck-Planche A, Scotti MT, de Paulo-Emerenciano V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr Pharm Design 2010; 16: 2656-65.
42. Vazquez-Naya JM, Martinez-Romero M, Porto-Pazos AB, et al. Ontologies of drug discovery and design for neurology, cardiology and oncology. Curr Pharm Design 2010; 16: 2724-36.
43. Mager PP. Reduced Free-Wilson approach applied to HSV-1 antiviral 7-amino-quinolines. Pharmazie 1990; 45: 359-60.
44. Gambino J, Focher F, Hildebrand C, et al. Quantitative structureactivity relationships of N2-phenylguanines as inhibitors of herpes simplex virus thymidine kinases. J Med Chem 1992; 35: 2979-83.
45. Hadjipavlou-Litina D. QSAR of N2-phenylguanidines as inhibitors of herpes simplex virus-1 thymidine kinase. Pharmazie 1995; 50: 796-8.
46. Gaudio AC, Richards WG, Takahata Y. QSAR and molecular graphics analysis of N2-phenylguanines as inhibitors of herpes simplex virus thymidine kinases. J Mol Graphics Model 2000; 18: 33-41.
47. Jenssen H, Gutteberg TJ, Lejon T. Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. J Pept Sci 2005; 11: 97-103.
48. Jenssen H, Gutteberg TJ, Rekdal O, Lejon T. Prediction of activity, synthesis and biological testing of anti-HSV active peptides. Chem Biol Drug Des 2006; 68: 58-66.
49. Artemenko AG, Muratov EN, Kuz'min VE, et al. Identification of individual structural fragments of N, N'-(bis-5-nitropyrimidyl) dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. J Antimicrob Chemother 2007; 60: 68-77.
50. Yudovin-Farber I, Gurt I, Hope R, Domb AJ, Katz E. Inhibition of herpes simplex virus by polyamines. Antivir Chem Chemother 2009; 20: 87-98.
51. Wakabayashi H, Takase M, Tomita M. Lactoferricin derived from milk protein lactoferrin. Curr Pharm Des 2003; 9: 1277-87.
52. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res 2002; 22: 2703-10.
53. Folkers G, Sakahara K, Schwobel W, Eger K. The development of pharmacophore models for thymidine kinase-dependent virostatic nucleoside analogs. Arch Pharm (Weinheim) 1989; 322: 395-8.
54. Haffey ML, Novotny J, Bruccoleri RE, Carroll RD, Stevens JT, Matthews JT. Structure-function studies of the herpes simplex virus type 1 DNA polymerase. J Virol 1990; 64: 5008-18.
55. Folkers G, Trumpp-Kallmeyer S, Gutbrod O, Krickl S, Fetzer J, Keil GM. Computer-aided active-site-directed modeling of the herpes simplex virus 1 and human thymidine kinase. J Comput Aided Mol Des 1991; 5: 385-404.
56. Selwood DL, Challand SR, Champness JN, et al. Isosteres of the DNA polymerase inhibitor aphidicolin as potential antiviral agents against human herpes viruses. J Med Chem 1993; 36: 3503-10.
57. Kussmann-Gerber S, Kuonen O, Folkers G, Pilger BD, Scapozza L. Drug resistance of herpes simplex virus type 1: structural considerations at the molecular level of the thymidine kinase. Eur J Biochem 1998; 255: 472-81.
58. Sun H, Zhi C, Wright GE, et al. Molecular modeling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase. J Med Chem 1999; 42: 2344-50.
59. Degreve B, Esnouf R, De Clercq E, Balzarini J. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine. Mol Pharmacol 2000; 58: 1326-32.
60. Barral K, Courcambeck J, Pepe G, et al. Synthesis and antiviral evaluation of cis-substituted cyclohexenyl and cyclohexanyl nucleosides. J Med Chem 2005; 48: 450-6.
61. Dahlroth SL, Gurmu D, Haas J, Erlandsen H, Nordlund P. Crystal structure of the shutoff and exonuclease protein from the oncogenic Kaposi's sarcoma-associated herpesvirus. FEBS J 2009; 276: 6636-45.
62. Derudas M, Carta D, Brancale A, et al. The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition. J Med Chem 2009; 52: 5520-30.
63. Spadola L, Novellino E, Folkers G, Scapozza L. Homology modelling and docking studies on Varicella Zoster Virus Thymidine kinase. Eur J Med Chem 2003; 38: 413-9.
64. Hernandez AI, Familiar O, Negri A, et al. N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem 2006; 49: 7766-73.
65. Hsiang CY, Ho TY. Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures. Br J Pharmacol 2008; 155: 227-35.
66. Biswas S, Miguel RN, Sukla S, Field HJ. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J Gen Virol 2009; 90: 1937-42.
67. Najjar AM, Nishii R, Maxwell DS, et al. Molecular-genetic PET imaging using an HSV1-tk mutant reporter gene with enhanced specificity to acycloguanosine nucleoside analogs. J Nucl Med 2009; 50: 409-16.
68. Lengauer T, Rarey M. Computational methods for biomolecular docking. Curr Opin Struct Biol 1996; 6: 402-6.
69. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004; 3: 935-49.
70. Olivier A, Creuven I, Evrard C, et al. Stereoelectronic properties of five anti-HSV-1 2'-deoxynucleosides analogues with heterocyclic substituents in the 5-position: a comparison with BVDU. Antivir Res 1994; 24: 289-304.
71. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature 1995; 373: 487-93.
72. Qiu X, Culp JS, DiLella AG, et al. Unique fold and active site in cytomegalovirus protease. Nature 1996; 383: 275-9.
73. Hoog SS, Smith WW, Qiu X, et al. Active site cavity of herpesvirus proteases revealed by the crystal structure of herpes simplex virus protease/inhibitor complex. Biochemistry 1997; 36: 14023-9.
74. Qiu X, Janson, CA, Culp JS, et al. Crystal structure of varicellazoster virus protease. Proc Natl Acad Sci USA 1997; 94: 2874-9.
75. Liu Y, Gong W, Huang CC, Herr W, Cheng X. Crystal structure of the conserved core of the herpes simplex virus transcriptional regulatory protein VP16. Gene Dev 1999; 13: 1692-703.
76. Vogt J, Perozzo R, Pautsch A, et al. Nucleoside binding site of herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography. Proteins 2000; 41: 545-53.
77. Zuccola HJ, Filman DJ, Coen DM, Hogle JM. The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C terminus of its cognate polymerase. Mol Cell 2000; 5: 267-78.
78. Grossmann JG, Sharff AJ, O'Hare P, Luisi B. Molecular shapes of transcription factors TFIIB and VP16 in solution: implications for recognition. Biochemistry 2001; 40: 6267-74.
79. Carfi A, Gong H, Lou H, et al. Crystallization and preliminary diffraction studies of the ectodomain of the envelope glycoprotein D from herpes simplex virus 1 alone and in complex with the ectodomain of the human receptor HveA. Acta Crystallogr D Biol Crystallogr 2002; 58: 836-8.
80. Connolly SA, Landsburg DJ, Carfi A, Wiley DC, Eisenberg RJ, Cohen GH. Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). J Virol 2002; 76: 10894-904.
81. Baker ML, Jiang W, Bowman BR, et al. Architecture of the herpes simplex virus major capsid protein derived from structural bioinformatics. J Mol Biol 2003; 331: 447-56.
82. Bird LE, Ren J, Wright A, et al. Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem 2003; 278: 24680-7.
83. Bowman BR, Baker ML, Rixon FJ, Chiu W, Quiocho FA. Structure of the herpesvirus major capsid protein. EMBO J 2003; 22: 757-65.
84. Connolly SA, Landsburg DJ, Carfi A, et al. Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. J Virol 2003; 77: 8127-40.
85. Gardberg A, Shuvalova L, Monnerjahn C, Konrad M, Lavie A. Structural basis for the dual thymidine and thymidylate kinase activity of herpes thymidine kinases. Structure 2003; 11: 1265-77.
86. Khayat R, Batra R, Qian C, Halmos T, Bailey M, Tong L. Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease. Biochemistry 2003; 42: 885-91.
87. Appleton BA, Loregian A, Filman DJ, Coen DM, Hogle JM. The cytomegalovirus DNA polymerase subunit UL44 forms a C clampshaped dimer. Mol Cell 2004; 15: 233-44.
88. Loregian A, Appleton BA, Hogle JM, Coen DM. Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit. J Virol 2004; 78: 9084-92.
89. Makhov AM, Taylor DW, Griffith JD. Two-dimensional crystallization of herpes simplex virus type 1 single-stranded DNAbinding protein, ICP8, on a lipid monolayer. Biochim Biophys Acta 2004; 1701: 101-8.
90. Moon AF, Edavettal SC, Krahn JM, et al. Structural analysis of the sulfotransferase (3-o-sulfotransferase isoform 3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1. J Biol Chem 2004; 279: 45185-93.
91. Schelling P, Claus MT, Johner R, Marquez VE, Schulz GE, Scapozza L. Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells. J Biol Chem 2004; 279: 32832-8.
92. Mapelli M, Panjikar S, Tucker PA. The crystal structure of the herpes simplex virus 1 ssDNA-binding protein suggests the structural basis for flexible, cooperative single-stranded DNA binding. J Biol Chem 2005; 280: 2990-7.
93. Marquez VE, Choi Y, Comin MJ, et al. Understanding how the herpes thymidine kinase orchestrates optimal sugar and nucleobase conformations to accommodate its substrate at the active site: a chemical approach. J Am Chem Soc 2005; 127: 15145-50.
94. Appleton BA, Brooks J, Loregian A, Filman DJ, Coen DM, Hogle JM. Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit. Differences in structure and function relative to unliganded UL44. J Biol Chem 2006; 281: 5224-32.
95. El Omari K, Liekens S, Bird LE, Balzarini J, Stammers DK. Mutations distal to the substrate site can affect varicella zoster virus thymidine kinase activity: implications for drug design. Mol Pharmacol 2006; 69: 1891-6.
96. El Omari K, Solaroli N, Karlsson A, Balzarini J, Stammers DK. Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design. BMC Struct Biol 2006; 6: 22.
97. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006; 313: 217-20.
98. Liu S, Knafels JD, Chang JS, et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006; 281: 18193-200.
99. Sprague ER, Wang C, Baker D, Bjorkman PJ. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol 2006; 4: e148.
100. Bagneris C, Ageichik AV, Cronin N, et al. Crystal structure of a vFlip-IKKgamma complex: insights into viral activation of the IKK signalosome. Mol Cell 2008; 30: 620-31.
101. Komazin-Meredith G, Santos WL, Filman DJ, Hogle JM, Verdine GL, Coen DM. The positively charged surface of herpes simplex virus UL42 mediates DNA binding. J Biol Chem 2008; 283: 6154-61.
102. Sudarman E, Bollati-Fogolin M, Hafner M, et al. Synthetic mimetics of the gp130 binding site for viral interleukin-6 as inhibitors of the vIL-6-gp130 interaction. Chem Biol Drug Des 2008; 71: 494-500.
103. Backovic M, Longnecker R, Jardetzky TS. Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci USA 2009; 106: 2880-5.
104. Baltz JL, Filman DJ, Ciustea M, et al. The crystal structure of PF-8, the DNA polymerase accessory subunit from Kaposi's sarcomaassociated herpesvirus. J Virol 2009; 83: 12215-28.
105. Makhov AM, Sen A, Yu X, Simon MN, Griffith JD, Egelman EH. The bipolar filaments formed by herpes simplex virus type 1 SSB/recombination protein (ICP8) suggest a mechanism for DNA annealing. J Mol Biol 2009; 386: 273-9.
106. Murayama K, Nakayama S, Kato-Murayama M, et al. Crystal structure of epstein-barr virus DNA polymerase processivity factor BMRF1. J Biol Chem 2009; 284: 35896-905.
107. Atanasiu D, Whitbeck JC, de Leon MP, et al. Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol 2010; 84: 3825-34.
108. Chowdary TK, Cairns TM, Atanasiu D, Cohen GH, Eisenberg RJ, Heldwein EE. Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 2010; 17: 882-8.
109. Silverman JL, Sharma S, Cairns TM, Heldwein EE. Fusiondeficient insertion mutants of herpes simplex virus type 1 glycoprotein B adopt the trimeric postfusion conformation. J Virol 2010; 84: 2001-12.
110. Offermanns S, Rosenthal W. Encyclopedia of Molecular Pharmacology. 2nd ed. Springer-Verlag: Berlin Heidelberg New York 2008.
111. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 1989; 29: 163-72.
112. Viswanadhan VN, Reddy MR, Bacquet RJ, Erion MD. Assessment of methods used for predicting lipophilicity: application to nucleosides and nucleoside bases J Comput Chem 1993; 14: 1019-26.
113. Estrada E, Gutierrez Y. Modeling chromatographic parameters by a novel graph theoretical sub-structural approach. J Chromatogr A 1999; 858: 187-99.
114. Estrada E, Gutierrez Y, Gonzalez H. Modeling diamagnetic and magnetooptic properties of organic compounds with the TOSSMODE approach. J Chem Inf Comput Sci 2000; 40: 1386-99.
115. Estrada E, Matamala AR. Generalized topological indices. Modeling gas-phase rate coefficients of atmospheric relevance. J Chem Inf Model 2007; 47: 794-804.
116. Estrada E, Pena A, Garcia-Domenech R. Designing sedative/hypnotic compounds from a novel substructural graphtheoretical approach. J Comput Aided Mol Des 1998; 12: 583-95.
117. Estrada E, Peña A. In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem 2000; 8: 2755-70.
118. Estrada E, Molina E. Novel local (fragment-based) topological molecular descriptors for QSpr/QSAR and molecular design. J Mol Graph Model 2001; 20: 54-64.
119. Speck-Planche A, Scotti MT, García-López A, et al. Design of novel antituberculosis compounds using graph-theoretical and substructural approaches. Mol Divers 2009; 13: 445-58.
120. Speck-Planche A, Scotti MT, Emerenciano VP, García-López A, Molina-Pérez E, Uriarte E. Designing novel antitrypanosomal agents from a mixed graph-theoretical substructural approach. J Comput Chem 2010; 31: 882-94.
121. Estrada E. Structure-mutagenicity relationships in 2-furylethylene derivatives. A molecular orbital study of the role of nitro groups. Mutat Res 1998; 420: 67-75.
122. Helguera AM, Cabrera Perez MA, Gonzalez MP, Ruiz RM, Gonzalez Diaz H. A topological substructural approach applied to the computational prediction of rodent carcinogenicity. Bioorg Med Chem 2005; 13: 2477-88.
123. Morales AH, Perez MA, Combes RD, Gonzalez MP. Quantitative structure activity relationship for the computational prediction of nitrocompounds carcinogenicity. Toxicology 2006; 220: 51-62.
124. Helguera AM, Gonzalez MP, Cordeiro MNDS, Perez MA. Quantitative structure carcinogenicity relationship for detecting structural alerts in nitroso-compounds. Toxicol Appl Pharmacol 2007; 221: 189-202.
125. Morales Helguera A, Perez Gonzalez M, Cordeiro MNDS, Cabrera Perez MA. Quantitative structure-carcinogenicity relationship for detecting structural alerts in nitroso compounds: species, rat; sex, female; route of administration, gavage. Chem Res Toxicol 2008; 21: 633-42.
126. Helguera AM, Perez-Machado G, Cordeiro MNDS, Combes RD. Quantitative structure-activity relationship modelling of the carcinogenic risk of nitroso compounds using regression analysis and the TOPS-MODE approach. SAR QSAR Environ Res 21: 277-304.
127. Estrada E. Edge adjacency relationship and a novel topological index related to molecular volume. J Chem Inf Comput Sci 1995; 35: 31-3.
128. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 1. Definition and applications for the prediction of physical properties of alkanes. J Chem Inf Comput Sci 1996; 36: 844-49.
129. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 2. Molecules containing heteroatoms and QSAR applications. J Chem Inf Comput Sci 1997; 37: 320-28.
130. Estrada E. Spectral moments of the edge adjacency matrix in molecular graphs. 3. Molecules containing cycles. J Chem Inf Comput Sci 1998; 38: 23-7.
131. Wang R, Fu Y, Lai L. A new atom-additive method for calculating partition coefficients. J Chem Inf Comput Sci 1997; 37: 615-21.
132. Ertl P, Rohde P, Selzer J. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000; 43: 3714-7.
133. Miller KJ. Additivity methods in molecular polarizability. J Am Chem Soc 1990; 112: 8533-42.
134. In ChEMBL Database 2010. Available at: http://www.ebi.-ac.uk/chembldb/.
135. Talete srl, DRAGON for Windows (Software for Molecular Descriptor Calculations). Version 5.3, 2005. Available at: http://-www.talete.mi.it/dragon.htm.
136. Estrada E, Gutiérrez Y. MODESLAB 1.5. © 2002-2004. Available at: www. modeslab.com.
137. Abraham MH. Scales of solute hydrogen-bonding: their application to physicochemical and biochemical processes. Chem Soc Rev 1993; 22: 73-83.
138. Platts JA, Butina D, Abraham MH, Hersey A. Estimation of molecular linear free energy relation descriptors using a group contribution approach. J Chem Inf Comput Sci 1999; 39: 835-45.
139. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 2003; 31: 3784-8.
140. ExPASy proteomics server. Available at: http://expasy.org/. In Swiss Institute of Bioinformatics: 1993.
141. Nilsson K, Gustafson L, Isaksson A, Hultberg B. Plasma homocysteine and markers of bone metabolism in psychogeriatric patients. Scandinavian J Clin Lab Invest 2005; 65: 671-80.
142. Morley C. OpenBabel, 2.2.3; 2006.
143. Van Waterbeemd H. Chemometrics methods in molecular design. Weinhiem, New York, Basel, Cambridge, Tokyo: VCH Publishers 1995.
144. STATISTICA 6.0 (data analysis software system) StatSoft, Inc: 2001.
145. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
146. Gonzalez-Diaz H, Prado-Prado FJ, Santana L, Uriarte E. Unify QSAR approach to antimicrobials. Part 1: predicting antifungal activity against different species. Bioorg Med Chem 2006; 14: 5973-80.
147. Prado-Prado FJ, Gonzalez-Diaz H, Santana L, Uriarte E. Unified QSAR approach to antimicrobials. Part 2: predicting activity against more than 90 different species in order to halt antibacterial resistance. Bioorg Med Chem 2007; 15: 897-902.
148. Prado-Prado FJ, Gonzalez-Diaz H, de la Vega OM, Ubeira FM, Chou KC. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg Med Chem 2008; 16: 5871-80.
149. Prado-Prado FJ, Martinez de la Vega O, Uriarte E, Ubeira FM, Chou KC, Gonzalez-Diaz H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg Med Chem 2009; 17: 569-75.
150. Prado-Prado FJ, Borges F, Perez-Montoto LG, Gonzalez-Diaz H. Multi-target spectral moment: QSAR for antifungal drugs vs. different fungi species. Eur J Med Chem 2009; 44: 4051-6.
151. Prado-Prado FJ, Borges F, Uriarte E, Perez-Montoto LG, Gonzalez-Diaz, H. Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species. Anal Chim Acta 2009; 651: 159-64.
152. Prado-Prado FJ, Garcia-Mera X, Gonzalez-Diaz H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem 2010; 18: 2225-31.
153. Munteanu CR, Magalhaes AL, Uriarte E, Gonzalez-Diaz H. Multitarget QPDR classification model for human breast and colon cancer-related proteins using star graph topological indices. J Theor Biol 2009; 257: 303-11.